Skip to main content

Table 1 Characteristics of included studies

From: Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis

Author, year

Country

Inclusion period

Median follow-up (months)

Total number of patients (n)

Patients with HER2-low/HER-0 (n)

HR status

Clinical T stage

Clinical N stage

Stage

NOS scale

De Moura Leite et al. 2021 [28]

Brazil

2007–2018

59

855

285/570

HR + and HR − 

T1–T4

N0–N3

13

8

Denkert et al. 2021 [19]

Europe

2012–2019

47

2310

1098/1212

HR + and HR − 

T1–T4

N0–N3

1–3

8

Kang et al. 2022 [29]

Korea

2014–2018

1572

754/818

HR + and HR − 

T1–T4

N0–N3

1–3

7

Jing‑Jing Li et al. 2023 [30]

China

2017–2017

59

283

239/44

HR + and HR − 

T1–T4

N0–N3

2–3

9

Qiao et al. 2023 [31]

China

2017–2021

20

132

70/62

HR + and HR − 

7

Shao et al. 2022 [32]

China

2017–2019

314

226/88

HR + and HR − 

T1–T4

N0–N3

2–3

7

Xu et al. 2023 [33]

China

2018–2021

24

429

267/162

HR + and HR − 

T1–T4

N0–N3

2–3

9

Garufi et al. 2023 [34]

Italy

53

566

340/226

HR + 

8

Pöschke et al. 2023 [35]

Germany

1998–2020

240 (20y)

1373

930/443

HR + and HR − 

T1–T4

N0 − N + 

1–3

7

Yang et al. 2023 [36]

China

2015–2017

177

117/60

HR + and HR − 

T1–T4

8

Dai et al. 2023 [37]

China

2015–2016

71

55

24/21

HR + and HR − 

1–3

8

Guochun Zhang et al. 2022 [38]

China

2016–2017

87

63/24

HR + and HR − 

T1–T4

N0–N3

1–3

7

Karakas et al. 2023 [39]

USA

2020–2021

49

130

75/55

HR + and HR − 

1–4

9

Ma et al. 2023 [40]

China

2015–2021

55

546

292/254

HR − 

T1–T4

N0–N3

1–3

7

Miglietta et al. 2022 [41]

Italy

2002–2018

261

105/156

HR + and HR − 

7

Alves et al. 2022 [42]

Portugal

2015–2020

36

72

41/31

HR + and HR − 

T1–T4

N0–N3

2–3

9

Ilie et al. 2023 [18]

France

2007–2018

54 (4.5y)

511

236/275

HR + and HR − 

T0–T4

N0–N3

1–3

8

Zhu et al. 2023 [43]

China

2009–2020

24

1473

1023/450

HR + and HR − 

7

Wang et al. 2023 [44]

China

2018–2022

18

148

93/55

HR + and HR − 

6

Toss et al. 2022 [45]

Italy

2008–2020

55

142

82/57

HR − 

T1–T4

N0 − N + 

9

Shi et al. 2023 [46]

China

2014–2022

430

249/181

HR + and HR − 

T1–T4

N0 − N + 

8

Nonneville et al. 2022 [47]

France

2005–2021

73

1111

456/655

HR + and HR − 

T0–T4

N0 −  ≥ N1

1–3

8

Huiyue Li et al. 2023 [48]

USA

2010–2018

65

45,331

28,172/17159

HR + and HR − 

T1–T4

N0–N3

7

Domergue et al. 2022 [49]

France

2005–2020

73

437

121/316

HR − 

T0–T4

N0 −  ≥ N1

1–3

9

Di Cosimo et al. 2022 [50]

Italy

2009–2020

60

444

335/109

HR + and HR − 

N0–N3

1–3

7

Shichao Zhang et al. 2023 [51]

China

2011–2022

40

3070

2340/730

HR + 

7

Yi et al. 2023 [52]

China

2017–2020

32

86

62/24

HR + and HR − 

T1–T4

N0–N3

1–3

9

Shiyuan Zhang et al. 2023 [53]

China

2011–2019

67

653

279/374

HR + and HR − 

T1–T4

N0–N3

1–3

8

Reinert et al. 2021 [54]

Brazil

NA

56

331

167/164

HR + and HR − 

7

Yijun Li et al. 2023 [55]

China

2010–2020

 

1027

678/349

HR + and HR − 

T1–T4

N0–N3

1–3

9

Jin et al. 2023 [56]

China

2013–2019

43

693

561/132

HR + and HR − 

T1–T3

N0–N3

9

Douganiotis et al. 2022 [57]

Grece

2007–2021

34

113

80/33

HR + 

8

Djurmez et al. 2023 [58]

Serbia

2020–2021

75

62/13

HR + and HR − 

8

Tarantino et al. 2024 [59]

USA

2016–2022

35 (2.94y)

991

491/500

HR + and HR − 

N0–N3

9

Tang et al. 2022 [60]

China

2012–2019

905

685/220

HR + and HR − 

T1–T4

N0–N3

7

Zhou et al. 2023 [61]

China

2016–2021

29.3

325

234/91

HR + and HR − 

T1–T4

N0–N3

1–3

8

Shao et al. 2024 [62]

China

2017–2020

410

293/117

HR + and HR − 

T1–T4

N0–N3

2–3

8

Tuluhong et al. 2023 [63]

China

2008–2019

72.7

246

157/89

HR + and HR − 

T1–T4

N0–N3

1–3

7

  1. HR hormone receptor; n number; y years; NOS Newcastle–Ottawa scale